idelalisib and Leukemia--Prolymphocytic--B-Cell

idelalisib has been researched along with Leukemia--Prolymphocytic--B-Cell* in 3 studies

Trials

1 trial(s) available for idelalisib and Leukemia--Prolymphocytic--B-Cell

ArticleYear
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
    British journal of haematology, 2019, Volume: 184, Issue:4

    Topics: Aged; Female; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Mutation; Purines; Quinazolinones; Remission Induction; Rituximab; Tumor Suppressor Protein p53; United Kingdom

2019

Other Studies

2 other study(ies) available for idelalisib and Leukemia--Prolymphocytic--B-Cell

ArticleYear
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
    British journal of haematology, 2019, Volume: 186, Issue:4

    Topics: Adenine; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Substitution; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retreatment; Rituximab; Signal Transduction; Sulfonamides; Treatment Outcome

2019
Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
    British journal of haematology, 2017, Volume: 177, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Genetic Variation; Humans; Leukemia, Prolymphocytic, B-Cell; Phenotype; Purines; Quinazolinones; Rituximab; Treatment Outcome; Tumor Suppressor Protein p53

2017
chemdatabank.com